Oncolytics Biotech Inc Stock Price, News & Analysis

Oncolytics Biotech Inc. (NASDAQ: ONCY) will host a conference call and webcast on May 5, 2022, at 5:00 p.m. ET to discuss its first-quarter financial results and corporate update. Pelareorep, an immunotherapeutic agent being developed by Oncolytics, is under evaluation for its efficacy in treating various cancers. The company is moving towards a registration study for metastatic breast cancer and is conducting clinical trials in combination with other therapies. Investors can access the webcast via the Investor Relations page on Oncolytics' website.

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced that CEO Dr. Matt Coffey will present a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2022, at 11:00 a.m. ET in Toronto. The conference will feature updates from Canadian healthcare companies and offer one-on-one investor meetings. A live webcast of the presentation will be available on Oncolytics' Investor Relations page and archived for three months. The company focuses on developing the immunotherapeutic agent pelareorep to enhance anti-cancer immune responses.

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced the publication of preclinical data showing that pelareorep significantly enhances the efficacy of CAR T cell therapy in treating solid tumors. The study, published in Science Translational Medicine, demonstrates that pelareorep-loaded CAR T cells exhibit improved persistence and anti-cancer activity in various murine solid tumor models. This combination may address key challenges faced by CAR T therapies in solid tumors, potentially increasing treatment options for patients. The findings suggest a promising avenue for clinical application.

Oncolytics Biotech (NASDAQ: ONCY) will have its Chief Medical Officer, Thomas Heineman, participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Virtual Conference.

Date: April 14, 2022
Time: 10:00 a.m. ET
Webcast: click here

Additionally, the company will engage in one-on-one investor meetings, highlighting its focus on developing pelareorep, an immunotherapeutic agent aimed at treating various cancers.

Oncolytics Biotech announced positive long-term results from the ReoGlio phase 1b trial, demonstrating pelareorep's potential in treating glioblastoma multiforme (GBM). A higher dose led to a median overall survival (mOS) of 50% at 24 months, with one patient alive at 42 months. The trial confirmed the treatment's favorable safety profile, supporting further studies. These findings suggest pelareorep may extend survival benefits beyond breast cancer to other challenging cancers. The results will be presented at the AACR Annual Meeting.

Oncolytics Biotech Inc. (NASDAQ: ONCY) announced new clinical data from a phase 1b trial of pelareorep in relapsed/refractory multiple myeloma patients. Notably, some patients achieved progression-free survival (PFS) exceeding three years despite prior treatment failures. This study illustrates pelareorep's ability to facilitate immune cell recruitment into the tumor microenvironment. The results increase understanding of pelareorep's mechanism and safety profile, paving the way for further clinical development in multiple cancers, including ongoing breast cancer trials.

Oncolytics Biotech (NASDAQ: ONCY) released a letter to shareholders detailing significant progress in its development pipeline during Q1 2022. The company remains on track to announce top-line data for its BRACELET-1 trial in Q4 2022, aimed at advanced HR+/HER2- breast cancer. Their collaboration with Roche in gastrointestinal cancers is on schedule, and they are advancing trials in China for pelareorep. The safety profile of pelareorep is highlighted as a key factor for business development, enhancing its potential in various cancer treatments.

Oncolytics Biotech announced the successful completion of a three-patient safety run-in for the third-line metastatic colorectal cancer cohort in its phase 1/2 GOBLET study. An independent review identified no safety concerns, allowing the trial to proceed to full enrollment with regulatory clearance from Germany's Paul Ehrlich Institute. The study, in collaboration with Roche, evaluates the efficacy of pelareorep combined with atezolizumab in several gastrointestinal cancer cohorts, including pancreatic and anal cancers. Previous data show a 90% clinical benefit rate in KRAS-mutated mCRC patients.

Oncolytics Biotech has announced that its partner, Adlai Nortye, has reached the third and final dose escalation cohort in the Chinese bridging trial for pelareorep in combination with paclitaxel, aimed at advanced breast cancer. The first two cohorts showed good tolerability with no new safety signals. This trial aligns with Oncolytics' North American studies and aims to facilitate regulatory submissions in key Asian markets, including China and Hong Kong. Significant survival benefits were noted from previous trials, furthering the potential for pelareorep's approval.